Perrigo Company plc Shareholders' Equity
Perrigo Company plc (PRGO) had Shareholders' Equity of $2.52 billion as of 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-27: Stockholders' Equity Attributable to Parent $2.52B.
- 2026-03-28: Stockholders' Equity Attributable to Parent $2.50B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $2.94B.
- 2025-09-27: Stockholders' Equity Attributable to Parent $4.45B.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-27 | $2.52B 10-Q · filed 2026-08-05 | |
| 2026-03-28 | $2.50B 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $2.94B 10-Q · filed 2026-08-05 | |
| 2025-09-27 | $4.45B 10-Q · filed 2025-11-05 | |
| 2025-06-28 | $4.47B 10-Q · filed 2026-08-05 | |
| 2025-03-29 | $4.36B 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $4.32B 10-Q · filed 2026-08-05 | |
| 2024-09-28 | $4.57B 10-Q · filed 2025-11-05 | |
| 2024-06-29 | $4.55B 10-Q · filed 2025-11-05 | |
| 2024-03-30 | $4.69B 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $4.77B 10-K · filed 2026-02-26 | |
| 2023-09-30 | $4.74B 10-Q · filed 2024-11-06 | |
| 2023-07-01 | $4.85B 10-Q · filed 2024-11-06 | |
| 2023-04-01 | $4.83B 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $4.84B 10-K · filed 2026-02-26 | |
| 2022-10-01 | $4.60B 10-Q · filed 2023-11-07 | |
| 2022-07-02 | $4.85B 10-Q · filed 2023-11-07 | |
| 2022-04-02 | $5.10B 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $5.15B 10-K · filed 2025-02-28 | |
| 2021-10-02 | $5.18B 10-Q · filed 2022-11-08 | |
| 2021-07-03 | $5.51B 10-Q · filed 2022-11-08 | |
| 2021-04-03 | $5.56B 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $5.66B 10-K · filed 2024-02-27 | |
| 2020-09-26 | $5.82B 10-Q · filed 2021-11-12 | |
| 2020-06-27 | $5.91B 10-Q · filed 2021-11-12 | |
| 2020-03-28 | $5.79B 10-Q · filed 2021-11-12 | |
| 2019-12-31 | $5.80B 10-K · filed 2023-02-28 | |
| 2019-09-28 | $5.76B 10-Q · filed 2020-11-05 | |
| 2019-06-29 | $5.73B 10-Q · filed 2020-11-05 | |
| 2019-03-30 | $5.70B 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $5.67B 10-K · filed 2022-03-01 | |
| 2018-09-29 | $5.66B 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $5.90B 10-Q · filed 2019-11-06 | |
| 2018-03-31 | $6.21B 10-Q · filed 2019-11-06 | |
| 2017-12-31 | $6.17B 10-K · filed 2021-03-01 | |
| 2017-09-30 | $6.04B 10-Q · filed 2017-11-09 | |
| 2017-07-01 | $6.08B 10-Q · filed 2017-08-10 | |
| 2017-04-01 | $6.07B 10-Q · filed 2017-05-30 | |
| 2016-12-31 | $5.96B 10-K · filed 2020-02-27 | |
| 2016-10-01 | $7.48B 10-Q/A · filed 2017-05-23 | $8.67B 10-Q · filed 2016-11-10 |
| 2016-07-02 | $9.05B 10-Q/A · filed 2017-05-22 | $9.90B 10-Q · filed 2016-08-10 |
| 2016-04-02 | $9.73B 10-Q/A · filed 2017-05-22 | $9.85B 10-Q · filed 2016-05-16 |
| 2015-12-31 | $10.11B 10-K · filed 2019-02-27 | $10.04B 10-KT · filed 2016-02-25 |
| 2015-09-26 | $10.73B 10-Q · filed 2015-11-02 | |
| 2015-06-27 | $10.70B 10-K · filed 2018-03-01 | $10.66B 10-K · filed 2015-08-13 |
| 2015-03-28 | $9.59B 10-Q · filed 2015-04-29 | |
| 2014-12-27 | $9.72B 10-Q · filed 2015-02-05 | |
| 2014-09-27 | $8.72B 8-K · filed 2014-11-20 | |
| 2014-06-28 | $8.72B 10-K · filed 2018-03-01 | $8.69B 10-K · filed 2014-08-14 |
| 2014-03-29 | $8.56B 10-Q · filed 2014-05-07 | |
| 2013-12-28 | $8.50B 10-Q · filed 2014-02-06 | |
| 2013-06-29 | $2.33B 10-K · filed 2017-05-22 | |
| 2012-06-30 | $1.85B 10-KT · filed 2016-02-25 | |
| 2011-06-25 | $1.53B 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |